Is Alunbrig (brigatinib) more potent than Xalkori (crizotinib)?
Alunbrig (brigatinib) and Xalkori (crizotinib) are both used for ALK-positive non-small cell lung cancer, but “more potent” depends on what measure you mean (tumor shrinkage at a given dose, lab potency like IC50, or clinical effectiveness).
What do the treatments’ real-world effectiveness and dosing suggest?
In clinical practice, brigatinib (Alunbrig) is generally considered a more effective option than crizotinib (Xalkori) for ALK-positive disease, especially after cancer progresses on or in comparison to crizotinib. This has led to brigatinib being used in settings where crizotinib historically had less durable control. However, that is an effectiveness/positioning statement, not a direct “potency at the same dose” comparison.
Do “potent” lab results (IC50) settle the question?
Not reliably. Potency from lab assays (like IC50 values) can vary by cell line, assay conditions, and ALK mutation context. So even if brigatinib shows lower IC50 in some experiments, it does not automatically translate into “more potent” in patients.
Which is “stronger” for ALK-positive tumors?
“Stronger” is best interpreted clinically: if your question is about which drug tends to control ALK-positive cancer better, brigatinib is often the preferred choice over crizotinib. If your question is literally about pharmacologic potency per milligram in the lab, you would need specific head-to-head potency data and assay context, which isn’t provided here.
If you tell me whether you mean lab potency (IC50), how quickly tumors shrink, or how well each works in treatment-naive vs previously treated ALK-positive patients, I can narrow the comparison to the right standard.